AIDS TREATMENT NEWS Issue #237, December 22, 1995
Mark Mascolini
The two completed studies, headed by Alexandra M. Levine, M.D., of the University of Southern California in Los Angeles, found that more than 1 in 5 people who had failed therapy with one or more lymphoma treatments responded to MGBG. Another 1 in 5 had stable disease after MGBG treatment. Although that response rate is not high, the 56 people in the two studies had advanced disease. Complete responses to MGBG lasted for about 6.6 months. Dr. Levine, who presented her results on December 5 at the annual meeting of the American Society of Hematology in Seattle, said she and other investigators suspect that MGBG will be more effective in people with newly diagnosed AIDS lymphoma, especially if it is combined with other antilymphoma drugs.
MGBG had been studied earlier for non-AIDS lymphoma but had too many side effects. Dr. Levine and her co-investigators seem to have overcome that problem by lowering the dose to 600 mg/m(2) given intravenously over 30 minutes once a week for 2 weeks, then every 2 weeks. With that regimen, MGBG has only relatively mild adverse effects on the production of blood cells. That would be an important advantage for people with AIDS lymphoma, because many antilymphoma drugs, as well as drugs such as AZT, can hurt the production of new blood cells.
951222
ATN23706
Copyright © 1995 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .